CRBP Corbus Pharmaceuticals Holdings Inc

$CRBP For Monday’s CRBP readout, the CANYON-1 cohort is: 240 adults with obesity randomized 1:1:1:1, so about: * 60 placebo * 60 on 20 mg CRB-913 * 60 on 40 mg * 60 on 60 mg Treatment is once daily for 12 weeks, followed by a 4-week safety follow-up. The higher-dose groups titrate up from 20 mg rather than starting immediately at 40 or 60 mg. Posting because some spreading lies about patients enrollment numbers.

$CRBP News dropping here on Monday Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity "today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity."

YVY Weekend Setup Board $CRBP Monday obesity data with major ATM risk $BLSM cancer data Monday night and the cleanest paper $LPTH record revenue with a $110.9M backlog $LTRX post earnings continuation setting up $ALMS $9.7M insider accumulation but needs a chart reclaim Catalysts filings dilution and levels all checked Full setups posted in YVY Community 💫 Which one runs first

$CRBP break of 10.50 to 11 and possibly 12 $MKDW see if it can dip to 6 for a move to 8 again $TNON support 5 so if that holds then 6 to 6.50 possible $XHLD with volume can tag 13 to 15 $FTFT 3 is res so if it can get volume to break that then 3.50/4 possible

$CRBP By hardcoding "highly peripherally restricted" directly into the opening summary sentence of the data-announcement PR, management is signaling that the primary hurdle—the central nervous system (brain) penetration that wrecked Novo Nordisk's drug—has been successfully cleared. They aren't hiding from the CB1 stigma; they are leading with their shield.

$CRBP Sooner or later (hopefully after ObesityWeek), analysts and the market will realize that CRB-913 has some potential to augment, compete with, or even displace GLP-1s. BP might pay a lot to own that potential and to keep it from the competition. The recent data removed the gravest doubts. With luck, the full dataset will confirm the pre-clinical research and increase the calculated odds of realizing each of those potential outcomes. In a truly rational market, those odds would largely determine the price. I'm sure it's higher than the company's cash holdings, where we now sit. The same logic applies to 701. And the combination of the two assets gives any potential buyers optionality - a Wall Street beloved.

$CRBP parabolic fall last 8 days, yesterday volume was massive, highest daily volume in at least 1 year.

$CRBP now this has become enticing, trading around cash value and the previous insider buy levels. Obesity pipeline was a non-factor for me

$CRBP Classic 'sell the news'. Love it. Why people chased AF on Friday is beyond me. The odds of a knockout readout was next to none. The only other option was to sell the news. Now we cycle through all the losers who chased. Once they sell and leave this will slowly creep back up. I will be adding everything sub $8. And with the current market volatility, I fully expect the sub $8's.

Waiting for Monday thankful data is coming out within Sept expiration. Was planning to add Oct strikes before next week was out but you never know. Imagine sitting on this having just seen your options expire...? For all we know stock gets roasted on Monday anyway, so a moot point. But I am a positivity person. And nothing better then making money while peoples lives are being improved, like many of these Bio names do... so I am cautiously hopeful... $CRBP

$CRBP - CB1 vs. GLP1 but my $TERN was bought out for $6.7 billion $CRBP stock price/valuation: At $25 a share $466 mil company At $50 a share $933 mil company at $100 a share $1.867 billion At $150 a share $2.8 billion

$CRBP Down 27% over the last few sessions. Wild! Totally expected as investors lock in profits ahead of a massive risk event. Buying small blocks on the way down.

$CRBP This is excellent news people. Remain calm. The world is fat! And there will never be enough drugs to treat all the fat nasty fuckers in this world.

$CRBP BFD, I shorted this bitch! It will be a couple of years and at least 3 capital raises before a NDA is even submitted.

$CRBP becomes enticing again sub $8. I imagine obesity data should mostly be priced in as a failure

$CRBP — Fear is high, and that’s exactly when opportunity shows up. CRB-913 doesn’t need to be perfect — it needs to show meaningful weight loss with a clean safety profile. If CANYON-1 confirms what we saw in Phase 1a, the market may have seriously underestimated this asset. Big catalyst. Big risk. Potentially much bigger reward. I’m buying the fear, not chasing the news. 🚀

$CRBP Those are the exact moments and situations when I won't look at my portfolio for a few weeks.

$CRBP I think the market is missing how good these results are. I get that a longer trial will be necessary to prove that weight loss continues and side-effects remain modest (better than GLP1s). But they've proven peripheral restriction works and that peripheral exposure induces weight loss. The commercial potential isn't fully proven, but it's high andf fairly likely now.

$CRBP He said that "psychiatric tolerability remains a question", they want further analysis to determine whether irritability relates to the drug or the weight loss .... the explanation is unresolved 🤫

$CRBP addition, more than 60% discontinue treatment within the first year. What I find particularly encouraging about the CANYON-1 study results is that weight reduction had not yet plateaued by the end of the 12-week treatment period, and that CRB-913 appears to have avoided the depressive effects associated with earlier central nervous system-acting cannabinoid receptor agonists. These findings support the potential emergence of the first agent in a new class of obesity medications, offering a novel mechanism of action to help treat the global epidemic of obesity.”